Michael Barbella, Managing Editor02.05.21
Cardiovascular Systems Inc.'s (CSI) newest independent board member is bringing a wealth of healthcare experience to his position.
Sachin H. Jain, M.D., is currently president and CEO of SCAN Group and Health Plan, a mission-driven organization dedicated to the health and wellness of older adults. Prior to this role, he was president and CEO of CareMore and Aspire Health. Before CareMore, Jain was chief medical information and innovation officer at Merck & Co. Prior to this role, Jain worked in leadership roles at the U.S. Department of Health and Human Services.
“We are pleased to welcome Dr. Sachin Jain as a new independent director to the CSI board,” said Scott Ward, chairman, president and CEO of CSI. “Sachin’s innovation and leadership in clinical practice, health policy, healthcare delivery and digital health will expand our Board’s understanding of key opportunities to prevent amputations and address disparities in healthcare.”
Jain is an adjunct professor of medicine at the Stanford University School of Medicine. In addition, Jain is a respected thought leader in health care delivery and has been recognized as a “Top 50 Most Influential Clinical Leader” and “100 Most Influential People in U.S. Healthcare” by Modern Healthcare. He currently serves as a member of the board of directors for America’s Health Insurance Plans, Abode Hospice, and the Make-A-Wish Foundation. He also serves as an Aspen Institute Health Innovator’s Fellow.
Jain graduated from Harvard College with a bachelor of arts degree in government and continued on to earn his medical degree from Harvard Medical School and MBA from Harvard Business School.
CSI’s board routinely reviews its composition to ensure it includes the necessary skills, experience and perspective to direct its business objectives. With the addition of Dr. Jain, four independent directors have joined CSI’s board since July 2019. The CSI board is comprised of nine directors, eight of whom are independent.
CSI is a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease.
Sachin H. Jain, M.D., is currently president and CEO of SCAN Group and Health Plan, a mission-driven organization dedicated to the health and wellness of older adults. Prior to this role, he was president and CEO of CareMore and Aspire Health. Before CareMore, Jain was chief medical information and innovation officer at Merck & Co. Prior to this role, Jain worked in leadership roles at the U.S. Department of Health and Human Services.
“We are pleased to welcome Dr. Sachin Jain as a new independent director to the CSI board,” said Scott Ward, chairman, president and CEO of CSI. “Sachin’s innovation and leadership in clinical practice, health policy, healthcare delivery and digital health will expand our Board’s understanding of key opportunities to prevent amputations and address disparities in healthcare.”
Jain is an adjunct professor of medicine at the Stanford University School of Medicine. In addition, Jain is a respected thought leader in health care delivery and has been recognized as a “Top 50 Most Influential Clinical Leader” and “100 Most Influential People in U.S. Healthcare” by Modern Healthcare. He currently serves as a member of the board of directors for America’s Health Insurance Plans, Abode Hospice, and the Make-A-Wish Foundation. He also serves as an Aspen Institute Health Innovator’s Fellow.
Jain graduated from Harvard College with a bachelor of arts degree in government and continued on to earn his medical degree from Harvard Medical School and MBA from Harvard Business School.
CSI’s board routinely reviews its composition to ensure it includes the necessary skills, experience and perspective to direct its business objectives. With the addition of Dr. Jain, four independent directors have joined CSI’s board since July 2019. The CSI board is comprised of nine directors, eight of whom are independent.
CSI is a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease.